Imugene (ASX:IMU)
ASX announcement history & article coverage
Transparent by design.
Announcments by Imugene (ASX:IMU) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Cleansing Notice
Application for quotation of securities - IMU
Change of Director's Interest Notice x4
Corporate Governance Statement and Appendix 4G
Appendix 4E and Annual Report
Imugene reports $105 million net loss with going concern uncertainty for FY2026
Notice under section 708A(12C)(e) of the Corporations Act
Notice of Initial Substantial Holding from SOL
Becoming a substantial holder from PCG
Notification regarding unquoted securities - IMU
Notification of cessation of securities - IMU
Application for quotation of securities - IMU
Amendment of Convertible Notes
Results of Extraordinary General Meeting
Letter To Shareholders
Expiry Of Listed Options
Final Director's Interest Notice - LC
Notification of cessation of securities - IMU
Quarterly Activities/Appendix 4C Cash Flow Report
Imugene advances azer-cel with FDA Fast Track, strong trial data, $27M capital raised, CEO resigns
Third response in concurrent BTKi Cohort of azer-cel Trial
Imugene reports third response in concurrent BTKi cohort of azer-cel Phase 1b trial
CEO Resignation
Imugene CEO Leslie Chong resigns after nearly 11 years; Board initiates leadership search
Notification of cessation of securities - IMU
Notice of Extraordinary General Meeting/Proxy Form
Cleansing Notice
Application for quotation of securities - IMU
Application for quotation of securities - IMU
Notification of cessation of securities - IMU
Change of Director's Interest Notice x5
Imugene Capital Raising Presentation
Proposed issue of securities - IMU
$11.1 Million Placement Completed to Advance azer-cel
Imugene raises $11.1 million placement to advance azer-cel after positive clinical data
Initial Director's Interest Notice - CG & MK
Trading Halt
New Complete Response in the Concurrent BTKi azer-cel Cohort
Imugene reports additional complete response in Phase 1b azer-cel BTKi cohort including first MCL patient
First Complete Response in Concurrent BTKi azer-cel Cohort
Imugene Reports First Complete Response in BTKi Cohort of Phase 1b Azer-cel Trial
Azer-cel Granted FDA Fast Track Designation for CLL and MZL
Imugene's Azer-cel Granted FDA Fast Track Designation for CLL/SLL and MZL
